Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Journal Club
  • Published:

BREAST CANCER

Nanotherapy: targeting the tumour microenvironment

Nature Reviews Cancer volume 22, page 258 (2022)Cite this article

Subjects

Access through your institution
Buy or subscribe

It is remarkable how a malignant cell orchestrates the acquired modifications for the purpose of sustainable tumour growth. Hypoxia, drug resistance and a low number of immunogenic antigens seen in many cancers, including breast cancer, are common barriers to chemotherapeutic efficacy in the tumour microenvironment (TME), leading to treatment failures. As a result, in recent years, research into TME-modifying drugs that improve drug effectiveness and promote antitumour immunity has shown promise in extending overall patient survival.

Amini et al. investigated a multimodal paradigm that combines bioreactive, TME-modulating hybrid polymer-lipid encapsulated manganese dioxide nanoparticles (PLMD-NPs) with doxorubicin (DOX). This combatted drug resistance mechanisms, reduced hypoxia and reversed immunosuppressive conditions by stimulating innate and adaptive immune responses, thereby blocking crosstalk between cancer cells and tumour-associated macrophages (TAMs) and improving chemotherapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Amini, M. A. et al. Combining tumor microenvironment modulating nanoparticles with doxorubicin to enhance chemotherapeutic efficacy and boost antitumor immunity. J. Natl Cancer Inst. 111, 399–408 (2019)

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Microbiology, Biochemistry & Immunology, Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA, USA

    Santosh Kumar Singh & Rajesh Singh

Authors
  1. Santosh Kumar Singh
    View author publications

    Search author on:PubMed Google Scholar

  2. Rajesh Singh
    View author publications

    Search author on:PubMed Google Scholar

Corresponding authors

Correspondence to Santosh Kumar Singh or Rajesh Singh.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Singh, S.K., Singh, R. Nanotherapy: targeting the tumour microenvironment. Nat Rev Cancer 22, 258 (2022). https://doi.org/10.1038/s41568-022-00461-6

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41568-022-00461-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer